Borderline resectable hepatocellular carcinoma: Definitions, efficacy and safety results from a prospective phase Ib/II study evaluating camrelizumab plus lenvatinib combined with TACE as preoperative therapy (BRHCC)

被引：0
|
作者：
Liao, M. [1 ]
Yang, Y. [2 ,5 ]
Jiang, H. [3 ]
Huang, J. [1 ]
Liu, C. [4 ]
Yang, Y. [2 ,5 ]
Xie, K. [6 ]
Luo, X. [7 ]
Zhou, J. [1 ]
Wang, X. [8 ]
Wu, H.
Zeng, Y. [9 ]
Li, Q. [5 ]
机构：
[1] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg & Lab Liver Surg, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Liver Transplant Ctr, Chengdu, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Gastroenterol & Hepatol, Chengdu, Peoples R China
[8] Sichuan Univ, West China Hosp, Div Abdominal Tumor Multimodal Treatment, Dept Radiat Oncol, Chengdu, Peoples R China
[9] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg & Lab Liver Surg, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
基金：
中国博士后科学基金;
关键词：
D O I：
10.1016/j.annonc.2024.08.1026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
966P
引用
收藏
页码：S664 / S665
页数：2
相关论文
共 50 条
  • [31] Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)
    Zang, M.
    Li, Q.
    Pang, H.
    Hu, X.
    Li, R.
    Yuan, G.
    Li, W.
    Guo, Y.
    Chen, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S874 - S874
  • [32] Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, singlearmed, real-world study
    Shao, G.
    Zeng, H.
    Sun, B.
    Zhu, K.
    Song, T.
    Si, T.
    Ji, J.
    Gu, S.
    Liu, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S597 - S597
  • [33] The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial
    Qiao, Qian
    Han, Chun
    Ye, Sisi
    Li, Juan
    Shao, Guoliang
    Bai, Yuxian
    Xu, Aibing
    Sun, Meili
    Wang, Wei
    Wu, Jian
    Huang, Ming
    Song, Lijie
    Huang, Luke
    Liu, Ting
    Liu, Wei
    Wang, Zhongmin Maxwell
    Li, Baiyong
    Xia, Michelle
    Bai, Li
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [34] TACE combined with tislelizumab and TKI as a conversion therapy in initial unresectable hepatocellular carcinoma (uHCC): A prospective single-arm phase II clinical study
    Liu, S.
    Lin, S.
    Luo, H.
    Luo, J.
    Mo, W.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S78 - S79
  • [35] Open-label, prospective phase 2 study to evaluate the efficacy and safety of camrelizumab combined with etoposide and cisplatin as neoadjuvant therapy in patients with neuroendocrine carcinoma of the cervix
    He, Haixin
    Yu, Haijuan
    Lin, Cuibo
    Lu, Yongwei
    Chen, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
    Katz, Matthew H. G.
    Varadhachary, Gauri R.
    Bauer, Todd W.
    Acquavella, Nicolas
    Merchant, Nipun B.
    Le, Tri Minh
    Javle, Milind M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC)
    Reig, Maria
    Evans, T. R. Jeffry
    Chon, Hong Jae
    Lim, Ho Yeong
    Ryu, Min-Hee
    Kim, Do Young
    Macarulla, Teresa
    Gomez-Martin, Carlos
    Moreno, Victor
    Haugk, Beate
    Ness, Thomas
    Baumann, Pia
    Bhoi, Sujata
    Jensen, Malene
    Tunblad, Karin
    Wallberg, Hans
    Oberg, Fredrik
    Heo, Jeong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 476 - 476
  • [38] Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
    Maohui Chen
    Yizhou Huang
    Shuliang Zhang
    Taidui Zeng
    Guanglei Huang
    Chun Chen
    Bin Zheng
    Trials, 24 (1)
  • [39] Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
    Lu, S.
    Zhang, W.
    Li, J.
    Hu, B.
    Li, X.
    Liu, Z.
    Wan, T.
    Tang, H.
    Liu, B.
    Cao, Y.
    Jiao, T.
    Zhang, Z.
    Wang, Y.
    Gao, B.
    Liu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S594 - S595
  • [40] Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
    Chen, Maohui
    Huang, Yizhou
    Zhang, Shuliang
    Zeng, Taidui
    Huang, Guanglei
    Chen, Chun
    Zheng, Bin
    TRIALS, 2023, 24 (01)
12345